NCT00260065View on ClinicalTrials.gov

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2008

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Decitabine

20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.

Trial Locations (21)

14263

Buffalo

29406

Charleston

30224

Griffin

33486

Boca Raton

34652

New Port Richey

35235

Birmingham

38138

Memphis

44718

Canton

53215

Milwaukee

54601

La Crosse

55905

Rochester

60153

Maywood

77030

Houston

79701

Midland

98104

Seattle

Unknown

Phoenix

Fort Myers

Jacksonville

60637-1470

Chicago

07601

Hackensack

M4N 3M5

Toronto

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT00260065 - A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter